As a result of accumulating evidence from clinical trials, SGLT2 inhibitors are now widely used as cardiorenal protective agents in patients with and without diabetes, especially as breakthrough agents that dramatically improve the prognosis of diabetic kidney disease. This evidence concerns the gene SLC5A2 and diabetic kidney disease.